These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26259316)

  • 1. Tc 99m Sestamibi Scanning in Multiple Myeloma--a New look with SPECT-CT.
    Luthra K; Bhave A; Lele RD
    J Assoc Physicians India; 2014 Sep; 62(9):801-12. PubMed ID: 26259316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy.
    Catalano L; Pace L; Califano C; Pinto AM; De Renzo A; Di Gennaro F; Del Vecchio S; Fonti R; Salvatore M; Rotoli B
    Haematologica; 1999 Feb; 84(2):119-24. PubMed ID: 10091409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
    Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
    Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
    Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
    Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease.
    Balleari E; Villa G; Garrè S; Ghirlanda P; Agnese G; Carletto M; Clavio M; Ferrando F; Gobbi M; Mariani G; Ghio R
    Haematologica; 2001 Jan; 86(1):78-84. PubMed ID: 11146575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: a five year single center experience.
    Villa G; Balleari E; Carletto M; Grosso M; Clavio M; Piccardo A; Rebella L; Tommasi L; Morbelli S; Peschiera F; Gobbi M; Ghio R
    J Exp Clin Cancer Res; 2005 Sep; 24(3):355-61. PubMed ID: 16270521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body (18)F-FDG PET identifies high-risk myeloma.
    Durie BG; Waxman AD; D'Agnolo A; Williams CM
    J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma.
    Hung GU; Tsai CC; Tsai SC; Lin WY
    Anticancer Res; 2005; 25(6C):4737-41. PubMed ID: 16334169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation.
    Svaldi M; Tappa C; Gebert U; Bettini D; Fabris P; Franzelin F; Osele L; Mitterer M
    Ann Hematol; 2001 Jul; 80(7):393-7. PubMed ID: 11529464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma.
    Mosci C; Pericole FV; Oliveira GB; Delamain MT; Takahashi MES; Carvalheira JBC; Etchebehere ECSC; Santos AO; Miranda ECM; Lima MCL; Amorim BJ; de Souza CA; Lorand-Metze I; Ramos CD
    Nucl Med Commun; 2020 Oct; 41(10):1081-1088. PubMed ID: 32732603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technetium-99m 2-methoxy-isobutyl-isonitrile uptake scintigraphy in detection of the bone marrow infiltration in multiple myeloma: correlation with MRI and other prognostic factors.
    Erten N; Saka B; Berberoglu K; Turkmen C; Unal S; Bakir B; Yekeler E; Besisik SK
    Ann Hematol; 2007 Nov; 86(11):805-13. PubMed ID: 17684742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tc99m-sestaMIBI uptake in nonsecretory multiple myeloma.
    Catalano L; Andretta C; Pace L; Del Vecchio S; Salvatore B; De Rosa G; Buonanno MT; Paone G; Rotoli B
    Hematology; 2005 Aug; 10(4):335-8. PubMed ID: 16085547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans.
    Mele A; Offidani M; Visani G; Marconi M; Cambioli F; Nonni M; Catarini M; Brianzoni E; Berbellini A; Ascoli G; Brunori M; Agostini V; Corvatta L; Isidori A; Spinelli A; Gradari M; Leoni P
    Br J Haematol; 2007 Mar; 136(5):729-35. PubMed ID: 17233770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate.
    Alexandrakis MG; Kyriakou DS; Passam F; Koukouraki S; Karkavitsas N
    Ann Hematol; 2001 Jun; 80(6):349-53. PubMed ID: 11475149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma.
    Mileshkin L; Blum R; Seymour JF; Patrikeos A; Hicks RJ; Prince HM
    Eur J Haematol; 2004 Jan; 72(1):32-7. PubMed ID: 14962260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myeloma.
    Koutsikos J; Athanasoulis T; Anagnostopoulos A; Velidaki A; Passadi M; Dimopoulos MA; Zerva C
    J Nucl Med; 2005 Jun; 46(6):978-82. PubMed ID: 15937309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
    Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
    Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scintigraphy using (99m)Tc-MIBI (sestamibi), a sensitive parameter of activity of multiple myeloma.
    Bacovsky J; Scudla V; Myslivecek M; Nekula J; Vytrasová M
    Neoplasma; 2005; 52(4):302-6. PubMed ID: 16059646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.